Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.43 |
| ▸ | KDM1A | O60341 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17846315 | 1.00 | SLC18A3 (0.54) | SLC18A3MEN1KMT2ACYP2D6CYP1A2 | |
| SCHEMBL4606954 | 1.00 | SLC18A3 (0.54) | SLC18A3MEN1KMT2ACYP2D6CYP1A2 | |
| SCHEMBL4606955 | 1.00 | SLC18A3 (0.54) | SLC18A3MEN1KMT2ACYP2D6CYP1A2 | |
| SCHEMBL15178310 | 1.00 | SLC18A3 (0.54) | SLC18A3MEN1KMT2ACYP2D6CYP1A2 | |
| SCHEMBL17846316 | 1.00 | SLC18A3 (0.54) | SLC18A3MEN1KMT2ACYP2D6CYP1A2 | |
| SCHEMBL407263 | 0.95 | SLC18A3 (0.59) | SLC18A3MEN1KMT2ACYP2D6CYP1A2 | |
| SCHEMBL1149307 | 0.95 | SLC18A3 (0.59) | SLC18A3MEN1KMT2ACYP2D6CYP1A2 | |
| SCHEMBL14026071 | 0.95 | SLC18A3 (0.59) | SLC18A3MEN1KMT2ACYP2D6CYP1A2 | |
| SCHEMBL3414993 | 0.95 | SLC18A3 (0.59) | SLC18A3MEN1KMT2ACYP2D6CYP1A2 | |
| SCHEMBL5163055 | 0.95 | SLC18A3 (0.59) | SLC18A3MEN1KMT2ACYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118422225-A | Preparation method of polysubstituted cyclic ether compound | 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) | 2024-08-02 | — | — | CN | claimed |
| CN-118422225-A | Preparation method of polysubstituted cyclic ether compound | 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) | 2024-08-02 | — | — | CN | disclosed |
| EP-3233858-B1 | ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| CN-104710283-B | Cyclopentanol compound | 国际香料和香精公司 | 2019-06-11 | — | — | CN | disclosed |
| US-9884048-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9845313-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-12-19 | — | — | US | disclosed |
| EP-3233858-A1 | ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| EP-3144300-A1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | Daiichi Sankyo Company, Limited (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-01-05 | — | — | US | disclosed |
| EP-1246797-B1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2008-07-23 | — | — | EP | disclosed |
| US-7279481-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20070167423-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2007-07-19 | — | — | US | disclosed |
| US-20040147612-A1 | Sulfonamide derivatives | DAVISON JOSHUA ZWICK (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1409452-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6639107-B1 | Potentiating glutamate receptor function | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
| WO-2002098846-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-12 | — | — | WO | disclosed |
| EP-1246797-A1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001042203-A1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-0414200-A2 | Salts of optically active 4-hydroxy-8-(3-lower alkoxy-4-phenylsulfinylphenyl)pyrazolo [1,5-a]-1,3,5-triazines and a process for production thereof | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1991-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | SLC18A3 2920/4885MEN1 2109/4885KMT2A 3239/4885 |
| US-20040147612-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, GRIA1 | SLC18A3 230/4885MEN1 4050/4885KMT2A 1168/4885 |
| US-20070167423-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | HTR1A, HTR1D, HTR1F | SLC18A3 238/4885MEN1 692/4885KMT2A 1284/4885 |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | TRPV1, TRPA1, SCNN1A | SLC18A3 616/4885MEN1 3769/4885KMT2A 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.